Product Detailed Description

liposomal Withanolide 3% — High Bioavailability Ashwagandha Steroidal Lactone Supplement

Product Overview

Liposomal Withanolide 3% is a premium-grade dietary supplement ingredient delivering withanolides in an advanced liposomal delivery system. Withanolides are a family of naturally occurring C₂₈ steroidal lactones unique to Ashwagandha (Withania somnifera), and are considered the major active components responsible for the adaptogenic, neuroprotective, and anti-inflammatory properties of this medicinal herb. Withanolide A (CAS 32911-62-9), the most extensively studied withanolide, has the molecular formula C₂₈H₃₈O₆ and a molecular weight of 470.6 g/mol. Withanolide D (CAS 30655-48-2) has the same molecular formula and molecular weight.

Ashwagandha, known as the “king of Ayurvedic herbs,” has been used for over 3,000 years in traditional Indian medicine for its immune-strengthening and anti-inflammatory properties. Withanolides, a family of steroid-derived molecules unique to Ashwagandha, have been shown to modulate inflammatory pathways in animal models, and several small randomized trials in humans support their effectiveness for reducing stress-related symptoms.

Why Liposomal Technology?

Conventional withanolides present significant bioavailability challenges. Despite withanolides being reported to have potent biological activities, there is a need to improve therapeutic efficacy as they have poor bioavailability, water solubility, and permeability. Their low bioavailability due to environmental and gastrointestinal factors limits efficacy.

Liposomal encapsulation provides four critical advantages:

1. Dramatically Enhanced Bioavailability and Solubility — Fabricating withanolides using phospholipid complexation (naturosomal delivery) increases the overall solubility by 14-fold and aqueous solubility by 1.3-fold, and enhances the stability and bioavailability of withanolides by more than 95%. PEGylated nano-liposomal Withanolide A was synthesized with high stability, having a particle size of 125 nm and 83.65% encapsulation efficiency.

2. Sustained Gastrointestinal Delivery — A nanoliposomal co-delivery system for withanolide A and bacoside A demonstrated a sustained release of 58.5 ± 2.93% of the bioactive compounds over 6 hours in simulated intestinal fluid, providing prolonged therapeutic action.

3. Enhanced Cellular Uptake and Targeted Delivery — Liposomal formulations enhance cellular uptake of withanolides. Encapsulated Withanolide A showed increased sustained release and significantly reduced cell growth in DLA and EAC cell lines compared to free withanolide. Liposomal-mediated withanolide delivery systems are highly effective for targeted therapeutic applications.

4. Enhanced Stability and Protection — The phospholipid bilayer shields withanolides from premature degradation during digestive transit, preserving their intact molecular structure until reaching optimal absorption sites in the small intestine.

Product Specifications

Key Features

• High Purity — Standardized to ≥3% total withanolides by HPLC, with higher concentrations available for concentrated applications.

• Liposomal Enhancement — Phospholipid complexation increases overall solubility by 14-fold and enhances bioavailability by more than 95%. PEGylated nano-liposomal Withanolide A achieves 125 nm particle size with 83.65% encapsulation efficiency.

• Neuroprotective Mechanisms — Withanolides inhibit amyloid-β protein oligomer aggregation, prevent tau protein hyperphosphorylation, and exert antioxidant effects by modulating the Keap-1/Nrf2 pathway. They also inhibit acetylcholinesterase and pseudo-cholinesterase, improving memory and cognition.

• Anti-Inflammatory Activity — Withanolides reduce inflammation by lowering pro-inflammatory markers, such as IL-1β, IL-6, MCP-1, and TNF-α, and prevent neuronal apoptosis by decreasing Bax/caspase-3 and cyto-c expression.

• Neuroplasticity Enhancement — Withanolides enhance neuroplasticity by increasing the levels of brain-derived neurotropic factor (BDNF) and glial fibrillary protein (GFAP), providing neuroprotection.

• Clinically Validated for Cognitive Function — Clinical trials have confirmed cognitive enhancement, memory improvement, and stress relief in patients with Alzheimer‘s disease. Current in vitro and in vivo data indicate that withanolides have strong potential to be effective treatments for Alzheimer’s disease.

• Superior Formulation Stability — Liposomal encapsulation protects withanolides from premature degradation, enabling sustained release and prolonged therapeutic activity.

• Water-Dispersible — Liposomal powder offers excellent dispersibility in aqueous systems; suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies have used standardized extracts containing anywhere from 0.2% to 35% withanolides, but the optimal amount of withanolides is not yet clear. For standardized extracts containing 1.5–5% withanolides (e.g., generic extracts), the typical dosage is 300–500 mg once or twice daily (total 300–1,000 mg/day). For extracts standardized to 5% withanolides (e.g., KSM-66®), the recommended dosage is 300–600 mg once or twice daily (total 300–1,200 mg/day). For extracts standardized to 10% withanolides (e.g., Sensoril®), the dosage range is 125–250 mg per day. A clinical trial is evaluating 1,000 mg daily of Ashwagandha root extract (standardized to <0.9% withanolides) for 3 months in adults with long COVID. For general stress management and cognitive support, 300–600 mg daily of a withanolide-standardized extract is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Important Safety Information: Ashwagandha is generally well tolerated at commonly used doses. Rare cases of liver injury have been reported with Ashwagandha supplementation, and individuals with pre-existing liver conditions should consult a healthcare professional before use. Ashwagandha may affect thyroid hormone levels and should be used with caution in individuals with thyroid disorders. Pregnant or lactating women and children should consult a healthcare professional before use. Ashwagandha may interact with immunosuppressant medications, sedatives, and thyroid medications.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.